“The Journey to End Cancer: From Cause to Cure” exhibition launches national tour with MD Anderson as presenting sponsor
Business Announcement
Updates every hour. Last Updated: 21-Jun-2026 21:16 ET (22-Jun-2026 01:16 GMT/UTC)
The University of Texas MD Anderson Cancer Center is pleased to announce the national launch of an innovative new science exhibition, showcasing the groundbreaking research, technologies and promising new therapies bringing progress in the mission to end cancer. “The Journey to End Cancer: From Cause to Cure,” presented by MD Anderson, will begin its national tour on March 7 at The Health Museum in Houston, followed by stops at multiple museums across the U.S. over five years.
Breast cancer (BC) is the most common cancer and the second leading cause of cancer death in women. It is a highly variable disease, defined as a malignancy of the epithelial ducts in breast tissue. Characterizing the vast heterogeneity within BC cells and their surrounding tumor microenvironment is crucial because this diversity is the primary reason for treatment resistance, disease progression and poor patient prognosis.
In a new study from Boston University Chobanian & Avedisian School of Medicine, researchers assembled a comprehensive single-cell atlas of the human breast, combining data from 138 patients and more than 600,000 single cells. They then were able to identify cell populations and cell states that previously were unclear or missed and linked these cell types to tumor features (like subtype and grade) and patient outcomes.
Cancer survivors who consumed higher amounts of ultraprocessed foods as part of their diet had a significantly increased risk of both all-cause and cancer-specific death.
Engineering multifunctional extracellular vesicles that can selectively and effectively kill lung cancer cells with minimal off‑target toxicity, offers a promising platform for next‑generation, precision‑guided cancer therapeutics.